4D Molecular Therapeutics, Inc.
FDMT

NASDAQ > Biotechnology
DCF:$12.21  |   P/E: -
$0.15(-2.38%)
Change
Rating:
Price: $6.31 USD
Market Cap: $284.76M

...Loading FDMT Peers...





4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

    147 Employees

    CEO : Dr. David H. Kirn M.D.

    Address : 5858 Horton Street, EmeryVille,CA, US, - 94608,

Key ExcutivesDesignation
Dr. Scott P. Bizily J.D., Ph.D.Chief Legal Officer & Corporate Secretary
Dr. An Song Ph.D.Chief Development Officer
Mr. Uneek MehraChief Financial & Business Officer
Dr. Robert Y. Kim M.B.A., M.D.Chief Medical Officer
Dr. Fariborz Kamal Ph.D.President & Chief Operating Officer
Dr. Noriyuki Kasahara M.D., Ph.D.Chief Scientific Officer
Dr. David H. Kirn M.D.Co-Founder, Chief Executive Officer & Director
Ms. Theresa JankeCo-Founder & Chief of Staff
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.Senior Vice President & Therapeutic Area Head of Pulmonology
Dr. John F. Milligan Ph.D.Executive Chairman